about
Vaccine adjuvants as potential cancer immunotherapeuticsThe Use of Synthetic Carriers in Malaria Vaccine DesignInfluenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.Role of CD8(+) T-cell immunity in influenza infection: potential use in future vaccine development.Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.In vitro cutaneous application of ISCOMs on human skin enhances delivery of hydrophobic model compounds through the stratum corneum.Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesiclesExploiting viral properties for the rational design of modern vaccines.Tubular immunostimulating complex based on cucumarioside A2-2 and monogalactosyldiacylglycerol from marine macrophytes.Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune PotentiatorsStructure of immune stimulating complex matrices and immune stimulating complexes in suspension determined by small-angle x-ray scattering.Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probesAdjuvant effects of saponins on animal immune responsesThe role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.Problems and emerging approaches in HIV/AIDS vaccine development.Improving vaccines by incorporating immunological coadjuvants.Promising particle-based vaccines in cancer therapy.Mucosal vaccination against tuberculosis using inert bioparticles.Peptide-based vaccines for cancer: realizing their potential.Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.Innate immune control of nucleic acid-based vaccine immunogenicity.Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.Adjuvants for allergy vaccinesEnhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Adjuvants in micro- to nanoscale: current state and future direction.Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?Peptide-based synthetic vaccines.Intranasal delivery of nanoparticle-based vaccines.Adjuvants for allergy immunotherapeutics.Current state and challenges in developing oral vaccines.Nanoparticulate Tubular Immunostimulating Complexes: Novel Formulation of Effective Adjuvants and Antigen Delivery Systems.Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B.Photochemical Internalization of Peptide Antigens Provides a Novel Strategy to Realize Therapeutic Cancer Vaccination.Intranasal administration of inactivated avian influenza virus of H5N1 subtype vaccine-induced systemic immune response in chicken and mice.Colloidal characteristics and formulation of pure protein particulate vaccines
P2860
Q26752522-74449111-2012-49AB-8507-6BACD8BF9EDBQ26777053-6915AE99-E6EB-4B4D-BE88-D11FC57ED216Q30353863-20A7068C-A418-44E3-B0F6-594E578BA442Q30359230-168D6C40-171F-40A7-9AE7-C9741E4A4961Q30389274-FF4B65CB-EFDE-476F-AF40-E052EABD2CE6Q30403760-4AE4BEE7-986C-4164-AF9A-678C85C46F7FQ31138173-5E0B2B61-BB68-44C1-A873-B77421CA3BC1Q33513233-37294143-08A0-4205-B4AE-CF8ACDEE0E3AQ34576021-7B71171B-09B9-4408-894A-FCEA9FD8B7FFQ34746490-0C04D5A6-E490-4193-A331-2EA07E7CD2D8Q35218546-F0864100-BC3E-451D-A780-7F7B234FDCD3Q35826747-D77AD36C-9DEB-40DE-8157-38C4FF932A5AQ35962580-404EB1EF-104F-4602-A6A5-C5AA1B76913EQ36216866-8797DD20-1920-480C-90ED-72B0BF12B86CQ36745550-4832B4D6-BF29-444B-8DFA-1E1D31D561CDQ36758235-ACC4D325-6572-4555-8105-D43F169207E9Q36758574-6106FF2F-832E-48A0-A5DF-C8EFCC66A858Q36899084-7C98770C-4826-4E7F-A47E-E1199749955FQ37259642-83CB6FB6-6EB1-42A6-A50B-E09A397903C8Q37264883-3CB467E8-9FFC-40A0-9A27-F6D0C3F53E4FQ37340462-D5201F6A-1AAB-43C5-AC39-103B98F660BFQ37523971-F57AE394-415B-4133-8D4E-6A9B0F5472EAQ37559651-9D5E1A1C-D94D-4867-B6B4-41314BB32EFEQ37857249-C2A621FF-9B7D-4FEC-93A9-C374B8A02A0DQ38055323-F3F9D751-260C-4859-8158-5AA391B567D6Q38282887-CE372640-8CC2-4DBC-9EEC-EFDA3665A389Q38461061-4414DDAC-BF40-4438-90BD-CDB6AF05D29AQ38520210-2A481A07-0005-4D53-A38D-DEFDD796187AQ38886698-8C747EC7-25F7-4583-ABE3-659D964996EAQ38914295-89F8AED9-9639-4F6A-97EB-2FFC4456573FQ39113247-8D3820D9-13E2-45F9-82FA-493E37761BB8Q39151158-DB388F2D-7772-4797-91F1-1E195E2656F4Q39259629-7CCB9266-1EC7-4167-8BFF-7A6BA59F0705Q41229756-CF01B667-3C1E-47CF-9468-7018BDAD52CCQ46816112-87EA808E-B70F-4D5A-95C6-D0FCD14DEABBQ52316326-0C465671-55B0-4334-A152-DB451544E0EFQ55230928-D3669145-4572-4563-9C2F-461EE8727CE8Q57835957-5F467ABC-6F4F-4473-BA07-4CFA27890919
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
ISCOM-based vaccines: the second decade.
@ast
ISCOM-based vaccines: the second decade.
@en
type
label
ISCOM-based vaccines: the second decade.
@ast
ISCOM-based vaccines: the second decade.
@en
prefLabel
ISCOM-based vaccines: the second decade.
@ast
ISCOM-based vaccines: the second decade.
@en
P2093
P2860
P1476
ISCOM-based vaccines: the second decade
@en
P2093
Georgia Deliyannis
Martin J Pearse
Megan T Sanders
P2860
P304
P356
10.1111/J.1440-1711.2005.01319.X
P577
2005-04-01T00:00:00Z